Use of an ang-(1-7) receptor agonist in acute lung injury

Abstract

The present invention refers to a peptidic or non-peptidic angiotensin(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.

1 .- 15 . (canceled) 
     
     
         16 . A method of treating acute lung injury in a subject comprising administering to a subject who is suffering from or susceptible to acute lung injury an Ang-(1-7) peptide comprising an amino acid sequence according to one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. 
     
     
         17 . The method of  claim 16 , wherein the acute lung injury is an acute respiratory distress syndrome. 
     
     
         18 . The method of  claim 16 , wherein the acute lung injury is related to a pulmonary or an extrapulmonary lung injury. 
     
     
         19 . The method of  claim 18 , wherein the pulmonary lung injury is selected from the group consisting of inhalation trauma, aspiration trauma, toxic lung oedema, lung infection, preferably pneumonia, lung contusion, and embolism. 
     
     
         20 . The method of  claim 18 , wherein the extrapulmonary lung injury is associated with a disorder selected from the group consisting of sepsis, polytrauma, shock, burn, acute pancreatitis, drug intoxication, alcohol abuse, chronic lung disease, mass transfusion, disseminated intravascular coagulation, erythema, and autoimmune lung disease. 
     
     
         21 . The method of  claim 16 , wherein the subject is a mammal, preferably a human, most preferably an adult human. 
     
     
         22 . A method of treating acute lung injury in a subject comprising administering to a subject who is suffering from or susceptible to acute lung injury a pharmaceutical composition comprising an Ang-(1-7) peptide comprising an amino acid sequence according to one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, and a pharmaceutically acceptable excipient. 
     
     
         23 . The method of  claim 22 , wherein the acute lung injury is an acute respiratory distress syndrome. 
     
     
         24 . The method of  claim 22 , wherein the acute lung injury is related to a pulmonary or an extrapulmonary lung injury. 
     
     
         25 . The method of  claim 24 , wherein the pulmonary lung injury is selected from the group consisting of inhalation trauma, aspiration trauma, toxic lung oedema, lung infection, preferably pneumonia, lung contusion, and embolism. 
     
     
         26 . The method of  claim 24 , wherein the extrapulmonary lung injury is associated with a disorder selected from the group consisting of sepsis, polytrauma, shock, burn, acute pancreatitis, drug intoxication, alcohol abuse, chronic lung disease, mass transfusion, disseminated intravascular coagulation, erythema, and autoimmune lung disease. 
     
     
         27 . The method of  claim 22 , wherein the subject is a mammal, preferably a human, most preferably an adult human. 
     
     
         28 . The method of  claim 22 , wherein the pharmaceutical composition is formulated for oral, intramuscular, intravenous, subcutaneous, topical, transdermal, rectal, vaginal, pulmonary, intranasal, intrabuccal, or sublingual administration. 
     
     
         29 . The method of  claim 28 , wherein, wherein the pharmaceutical composition is formulated as a tablet, pill, capsule, granules, a syrup, a spray, an aerosol, a liposomal composition, an ointment, a suppository, an implant, a plaster, or a slow release formulation. 
     
     
         30 . The method of  claim 28 , wherein the pharmaceutical composition further comprises one or more pharmacologically inert and pharmacologically acceptable excipients such as a polymer carrier, a distintegration agent, a lubricant, a solvent, or a swelling agent.